Peijia Medical's TaurusTrio TAV system gets NMPA approval

Peijia Medical Limited has received approval from the National Medical Products Administration (NMPA) of the People's Republic of China for the registration application of its TaurusTrio™ Transcatheter Aortic Valve (TAV) system on December 11, 2025. This voluntary announcement highlights a key development in the group's business and product pipeline.

The TaurusTrio™ TAV system, developed and manufactured by Peijia Medical under an exclusive license from JenaValve Technology, Inc., is designed to treat patients with severe aortic regurgitation (AR) via transfemoral access. The system addresses a critical unmet need for AR patients who often lack calcification for traditional TAV anchoring, utilizing proprietary locator technology for secure attachment to native leaflets even without calcium.

JenaValve's Trilogy™ THV System, the basis for TaurusTrio™, received CE Mark approval in May 2021 and has been used in over 1,000 commercial procedures globally. Peijia Medical anticipates that the TaurusTrio™ TAV system will provide a safe and effective treatment option for Chinese patients suffering from severe AR.